Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Dual/triple agonist, GLP-1RA, Insulin Delivery, Other, Topics Sep 20 | 2024Novo CB1 Ph2a Obesity Topline Results; Two Ph3 Tirzepatide Combo Psoriatic Studies Observed; Aligos Ph2a MASH Topline Results; AZ Initiates Ph2 LA Amylin Obesity Study; FTC Sues PBMs; Synjardy Receives Pediatric CHMP Positive OpinionPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Sep 19 | 2024Wegovy HFpEF CHMP Opinion; Lilly Amylin+Tirzepatide Obesity Study; Another Compounded Semaglutide and Tirzepatide; Tandem t:slim X2 Compatible with LyumjevPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other Sep 18 | 2024Novo Enters Partnership with NanoVation for Cardiometabolic and Rare Diseases; Lilly and Axcelead Enter Development PartnershipPurchase Blast
$599
Posted in: Glucose Monitoring, Other Sep 17 | 2024Eversense 365 Day CGM Receives FDA ClearancePurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucagon, Other Sep 16 | 2024September CHMP Agenda; Novo Collaboration with Korro; Jeff Wade Leaves LexiconPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other Sep 16 | 2024Roche in Damage Control Mode After EASD Obesity Data ReadoutPurchase Blast
$599
Posted in: Basal Insulin, GLP-1RA Sep 12 | 2024EASD 2024 Key Press Releases (Sep 11)Purchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucagon, Other, SGLT2i Sep 10 | 2024EASD 2024 Key Press Releases (Sep 10)Purchase Blast$599
Posted in: Dual/triple agonist, GLP-1RA, Other Sep 09 | 2024EASD 2024 Key Press Releases (Sep 09)Purchase Blast
$599
Posted in: Other Sep 09 | 2024FENIX Interview with TIXiMED - Oral T1DM Therapeutic DeveloperPurchase Blast
$599
Posted in: Basal Insulin, GLP-1RA, Other Sep 06 | 2024Lilly QW Insulin QWINT-1 and -3 Topline Results; Lilly Initiates Ph3 Orforglipron Maintenance Study; Lilly-Backed OrsoBio Raises $67M in Series B for Obesity DevelopmentPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring, Other Sep 05 | 2024Abbott Launches Lingo OTC CGM in the USPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other Sep 04 | 2024Abbott Partners with Beta Bionics; Dexcom at Wells Fargo; Lilly Partners for Drug Discovery; AZ Initiates Oral GLP-1RA Ph2b Trial in T2DM; BioAge Files for IPO; Bayer, Arrowhead, and Lexicon Data at ESC 2024; Esperion Secures Additional Nexletol/Nexlizet Coverage; Skye Appoints New CMO; Scholar Rock Appoints New CBOPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other Aug 30 | 2024Novo Initiates Ph1 Study for New Obesity Asset; Lemonaid GLP-1RA and Compounded Semaglutide Program; New Semaglutide HF Analysis Published; Alnylam’s Ph3 ATTR-CM Vutrisiran DataPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Glucose Monitoring, Other Aug 28 | 2024Dexcom Hosts Stelo Webinar; Libre 3 CGM Recall; Novartis Positive Ph3 Leqvio Trial Results; President Biden Releases Statement on AOM PricesPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Insulin Delivery, Other Aug 27 | 2024Lilly Launches Single-Dose Zepbound Vials; Omnipod 5 T2DM Approval; Novo Semaglutide Adolescent Obesity StudyPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other Aug 27 | 2024FENIX Analysis: Pump/AID Promotional Materials Post-ADA 2024Purchase Blast
$599
Posted in: Glucose Monitoring, Other Aug 26 | 2024Dexcom launches Stelo OTC Glucose Biosensor in the USPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other Aug 23 | 2024Novo Ph1 GLP/GIP RA Obesity Study; Pfizer Ph1 Danuglipron Study; D&D Ph2b MASH Study; Skye Ph2 Nimacimab Obesity Trial Initiation; FDA Denies Intarcia’s T2DM DevicePurchase Blast